Simcere Pharmaceutical Group (SCR) Posts Mixed Q2 Results
Tweet
Share
E-mailGet Alerts SCR Hot Sheet
Join SI Premium – FREE
Simcere Pharmaceutical Group (NYSE: SCR) reported Q2 EPS of $0.21, $0.08 better than the analyst estimate of $0.13. Revenue for the quarter came in at $84.4 million versus the consensus estimate of $90.61 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
- VNET Group (VNET) Misses Q2 EPS by 164c
- Hesai Group (HSAI) Tops Q1 EPS by 8c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
